What "research use only" means

The short answer

"Research use only" is a warning that a product is not meant for medical use in people. It is not an approval, a safety rating or a quality standard. Putting the label on a vial does not make it legal to sell that vial for people to use.^[1][2]

Where the label comes from

In FDA rules, "research use only" is a formal label for lab products, mostly diagnostic test kits and reagents, that are still in the research stage. These products are not meant to produce results used to diagnose or treat patients. FDA guidance calls for a prominent warning on them saying they are for research use only and not for use in diagnosis.^[1]

FDA describes the label as a warning to keep a product out of patient care. It says that simply placing the label on a product does not excuse it from the rules that would otherwise apply.^[1]

What "research use only" does not mean

• It does not mean tested in people. To give an unapproved drug to people in a study, a sponsor normally files an Investigational New Drug application with FDA first.^[3] A research label is not that.
• It does not mean approved or compounded. Approved drugs go through FDA review. Compounded drugs are not FDA approved, but they are made by pharmacies under specific laws.^[4] A research chemical is neither.
• It does not mean safe or sterile. FDA says the quality of research labeled weight loss peptides sold to consumers is unknown and they may be harmful.^[5] A study that bought research labeled semaglutide online found every product substandard or falsified.^[6]

How FDA looks at research labels on products sold to people

FDA does not judge a product by its disclaimer alone. It looks at the whole picture: the labeling, advertising, promotion, product names and how the product is sold and to whom.^[1] That guidance was written for diagnostic products, but FDA warning letters to peptide sellers follow the same logic.

• In December 2024, FDA warned a seller whose vials of semaglutide, retatrutide, cagrilintide, tirzepatide and mazdutide said "research use only." Its website described diabetes and obesity uses, and its Facebook page promoted weight loss. FDA said the products were unapproved new drugs meant for people.^[2]
• In February 2025, FDA warned another seller that used "research use only," "not for human consumption" and "lab purposes only" disclaimers. It also sold bacteriostatic water and insulin syringes for the injectable products. FDA said the disclaimers did not change the fact that the products were intended for human use.^[7]
• FDA's current page on unapproved GLP-1 drugs says it has warned companies selling these drugs labeled "for research purposes" or "not for human consumption" directly to consumers with dosing instructions. FDA urges people not to buy them.^[5]

The same pattern shows up outside weight loss drugs. FDA has noted that BPC-157 is sold in blends labeled "for research purposes only."^[8]

Signs the label is a disguise

Based on what FDA cites in its letters, the research label is likely cover when a seller:

• Describes health benefits, conditions or body effects on its site or social media.^[2]
• Gives dosing or injection directions.^[5][6]
• Sells syringes or mixing water alongside the product.^[7]
• Sells to anyone with a card, with no check that the buyer is a lab.

What real research use looks like

Real lab research happens in labs, with oversight. When researchers want to give an unapproved drug to people, the sponsor files an IND, and FDA reviews it for safety for 30 days before a trial can begin.^[3] A person buying a vial online for their own use is not doing research under these rules.

Bottom line

"Research use only" tells you the seller is not promising the product is fit for people. Take that warning at face value.

Sources

1. U.S. Food and Drug Administration. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only, Guidance for Industry and FDA Staff. November 2013. FDA guidance (PDF)
2. U.S. Food and Drug Administration. Warning Letter to Summit Research Peptides, MARCS-CMS 695607. December 10, 2024. FDA warning letter
3. U.S. Food and Drug Administration. Investigational New Drug (IND) Application. FDA page
4. U.S. Food and Drug Administration. Compounding Laws and Policies. FDA page
5. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Updated October 1, 2026. FDA safety page
6. Ashraf AR, Mackey TK, Vida RG, et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res. 2024;26:e65440. doi:10.2196/65440
7. U.S. Food and Drug Administration. Warning Letter to USApeptide.com, MARCS-CMS 696885. February 26, 2025. FDA warning letter
8. U.S. Food and Drug Administration. FDA Evaluation of BPC-157 Related Bulk Drug Substances. Briefing document, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. FDA briefing document (PDF)